INVESTIGADORES
ABRAHAM Gustavo Abel
congresos y reuniones científicas
Título:
Risperidone loaded PCL-PEO-PCL nanospheres: in vitro release results
Autor/es:
L.C. HERRERA; L.G. HERMIDA; G.A. ABRAHAM; F. BUFFA; P.E. LLORET; G.O. YBARRA
Lugar:
Maryland, U.S.A.
Reunión:
Congreso; 38th Annual Meeting and Exposition of the Controlled Release Society; 2011
Institución organizadora:
Controlled Release Society
Resumen:
A PCL-PEO-PCL triblock copolymer was synthesized and used to prepare risperidone nanospheres. Emulsifier and drug-polymer concentration were varied to obtain different release systems which were analyzed by AFM and DLS. Encapsulation efficiency and in vitro release profiles were also determined. Encapsulation efficiencies varied depending on the surfactant and the drug-polymer concentration used. Risperidone nanospheres presented a prolonged release except for those prepared with PVA at a high drug-polymer concentration which rapidly released the drug. Risperidone is a lipophilic drug employed for the treatment of schizophrenia and bipolar disorder. PLGA microspheres have been developed and marketed to achieve a prolonged release of risperidone. This system allows a constant therapeutic concentration in plasma for fifteen days avoiding daily administration. PLA nanosuspensions of risperidone have also been prepared and evaluated in vitro. Nevertheless the high cost of this polymer has led to look for alternatives based on other biocompatible polymers. Poly(e-caprolactone) (PCL) is a biodegradable aliphatic polyester approved by the FDA for various applications in the biomedical field. PCL-risperidone nanoparticles have been obtained with high encapsulation efficiencies but a too fast release of the drug. PCL-PEO-PCL triblock copolymers have also been proposed for biomedical applications. These copolymers combine the hydrophilicity of the central PEO block with the degradability of PCL and show bulk degradation and further resorb in vivo through natural pathways. The aim of this work is to prepare and characterize PCL-PEO-PCL-risperidone nanospheres as a first approach to select the most appropriate delivery system for risperidone therapeutic administration.
